Drugs / bone marrow-derived progenitor cells
bone marrow-derived progenitor cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00279175 | Apr 2004 → Oct 2005 | myocardial infarction | A. M. Zeiher | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow-derived progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00279175 ↗ |
| Known as | BMC | “we randomly assigned 204 patients with acute myocardial infarction to receive an intracoronary infusion of progenitor cells derived from bone marrow (BMC) or placebo medium...” PMID 16990384 ↗ Sep 2006 |
| Known as | BMCs | “The Doppler Substudy of the randomized, double-blind, placebo-controlled Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction...” PMID 17620510 ↗ Jul 2007 |
| Modality | Cell therapy | “randomly assigned to either stem cell therapy (bone marrow-derived progenitor cells [BMC]) or placebo after bone marrow aspiration” PMID 19249426 ↗ Jan 2009 |
| Route | Other | “intracoronary infusion of progenitor cells derived from bone marrow” PMID 16990384 ↗ Sep 2006 |